Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This study is the single-center, open-label phase I clinical trial to evaluate tolerability,
safety and efficacy of Donafenib and JS001 in combination with TCAE in patients with
Unresectable Hepatocellular Carcinoma.